Two-Part Cell Therapy Aims to Cure Type 1 Diabetes

Engineering Immune Bodyguards

The more innovative half of the therapy addresses the rejection problem with a technique borrowed from cancer immunotherapy. The team engineers regulatory T cells — immune cells naturally responsible for preventing the immune system from attacking the body's own tissues — using chimeric antigen receptors, the same CAR technology that has revolutionized certain cancer treatments.

These CAR-modified Tregs are designed to recognize specific proteins on the surface of the transplanted beta cells. When a Treg detects its target protein on a beta cell, it signals the surrounding immune system to stand down — effectively creating a localized zone of immune tolerance around the transplanted cells.

The elegance of this approach lies in its specificity. Rather than suppressing the entire immune system, as conventional anti-rejection drugs do, the engineered Tregs provide targeted protection only where it is needed. The rest of the immune system continues to function normally, maintaining the body's defenses against infection and disease.

Preclinical Promise

In mouse studies using humanized immune system models developed by collaborator Michael Brehm at the University of Massachusetts Medical School, the protective effects of the engineered Tregs lasted up to one month — the longest period studied so far. While one month may sound brief, it represents proof of concept that the approach works in a living immune system, not just in laboratory cell cultures.

The new funding will support research into extending the duration of protection and determining whether multiple doses of engineered Tregs could produce longer-lasting or even permanent immune tolerance. The team will also investigate the optimal ratio of protective Tregs to transplanted beta cells and the best delivery methods for both cell types.

Why This Matters Beyond Diabetes

The immune engineering platform being developed for type 1 diabetes has implications that extend well beyond a single disease. If engineered Tregs can create durable immune tolerance for transplanted beta cells, the same approach could potentially protect other types of transplanted cells and organs.

Kidney, liver, and heart transplant recipients currently face the same immunosuppression burden that limits beta cell transplants. A targeted immune tolerance approach could transform transplant medicine broadly, reducing rejection rates while eliminating the side effects of systemic immunosuppression.

The Road Ahead

Ferreira is clear-eyed about the ambition of the project: the goal is a therapy that works for all people with type 1 diabetes at every stage of the disease, including those who have lived with it for decades. This is a higher bar than many previous approaches, which focused on newly diagnosed patients whose immune attacks might be more easily controlled.

The path from preclinical mouse studies to human therapy will require years of additional development, safety testing, and clinical trials. Manufacturing challenges for both the beta cells and the engineered Tregs must be solved at scale. Regulatory pathways for a two-component cell therapy of this complexity have few precedents.

Yet the convergence of stem cell manufacturing, CAR-T engineering, and humanized animal models creates a research foundation that makes this attempt credible in a way that earlier cure efforts were not. The million-dollar grant is a starting point, not a finish line — but for the first time in the century since insulin's discovery, a genuine cure appears within reach of the science.

This article is based on reporting by Science Daily. Read the original article.